BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim MK, Kim HS, Kim SH, Oh JM, Han JY, Lim JM, Juhnn YS, Song YS. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol 2010;80:1930-5. [PMID: 20643111 DOI: 10.1016/j.bcp.2010.07.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hemmat N, Baghi HB. Human papillomavirus E5 protein, the undercover culprit of tumorigenesis. Infect Agent Cancer 2018;13:31. [PMID: 30455726 DOI: 10.1186/s13027-018-0208-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
2 Liao S, Deng D, Zeng D, Zhang L, Hu X, Zhang W, Li L, Jiang X, Wang C, Zhou J, Wang S, Zhang H, Ma D. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo. J Huazhong Univ Sci Technol [Med Sci ] 2013;33:735-42. [DOI: 10.1007/s11596-013-1189-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
3 Yuan CH, Filippova M, Duerksen-Hughes P. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses 2012;4:3831-50. [PMID: 23250450 DOI: 10.3390/v4123831] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
4 Rasi Bonab F, Baghbanzadeh A, Ghaseminia M, Bolandi N, Mokhtarzadeh A, Amini M, Dadashzadeh K, Hajiasgharzadeh K, Baradaran B, Bannazadeh Baghi H. Molecular pathways in the development of HPV-induced cervical cancer. EXCLI J 2021;20:320-37. [PMID: 33746665 DOI: 10.17179/excli2021-3365] [Reference Citation Analysis]
5 Cossar LH, Schache AG, Risk JM, Sacco JJ, Jones NJ, Lord R. Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer. Clin Oncol (R Coll Radiol) 2017;29:626-34. [PMID: 28336131 DOI: 10.1016/j.clon.2017.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Boumba LM, Assoumou SZ, Hilali L, Mambou JV, Moukassa D, Ennaji MM. Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates. Infect Agent Cancer 2015;10:15. [PMID: 25991921 DOI: 10.1186/s13027-015-0010-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
7 Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis 2019;77:ftz048. [PMID: 31504464 DOI: 10.1093/femspd/ftz048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
8 Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY, Lu WG, Xie X. Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 2011;47:2166-74. [PMID: 21636267 DOI: 10.1016/j.ejca.2011.04.037] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
9 Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011;10:140. [PMID: 22078316 DOI: 10.1186/1476-4598-10-140] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 12.5] [Reference Citation Analysis]
10 Ganguly N. Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. Cell Oncol 2012;35:67-76. [DOI: 10.1007/s13402-011-0069-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
11 de Freitas AC, Coimbra EC, Leitão Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta 2014;1845:91-103. [PMID: 24388872 DOI: 10.1016/j.bbcan.2013.12.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
12 Kanazawa T, Fukushima N, Imayoshi S, Nagatomo T, Kawada K, Nishino H, Misawa K, Ichimura K. Rare case of malignant transformation of recurrent respiratory papillomatosis associated with human papillomavirus type 6 infection and p53 overexpression. Springerplus 2013;2:153. [PMID: 23641321 DOI: 10.1186/2193-1801-2-153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
13 de Almeida VH, de Melo AC, Meira DD, Pires AC, Nogueira-Rodrigues A, Pimenta-Inada HK, Alves FG, Moralez G, Thiago LS, Ferreira CG, Sternberg C. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer. Braz J Med Biol Res 2017;51:e6822. [PMID: 29160417 DOI: 10.1590/1414-431X20176822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Gupta AK, Kumar M. HPVomics: An integrated resource for the human papillomavirus epitome and therapeutics. Genomics 2020;112:4853-62. [PMID: 32871223 DOI: 10.1016/j.ygeno.2020.08.025] [Reference Citation Analysis]
15 Abbas M, Mehdi A, Khan FH, Verma S, Ahmad A, Khatoon F, Raza ST, Afreen S, Glynn SA, Mahdi F. Role of miRNAs in cervical cancer: A comprehensive novel approach from pathogenesis to therapy. J Gynecol Obstet Hum Reprod 2021;50:102159. [PMID: 33965650 DOI: 10.1016/j.jogoh.2021.102159] [Reference Citation Analysis]
16 Hemmat N, Baghi HB. The interaction of human papillomaviruses and adeno-associated viruses in suppressive co-infections. Infect Genet Evol 2019;73:66-70. [PMID: 31026603 DOI: 10.1016/j.meegid.2019.04.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Ilahi NE, Bhatti A. Impact of HPV E5 on viral life cycle via EGFR signaling. Microbial Pathogenesis 2020;139:103923. [DOI: 10.1016/j.micpath.2019.103923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
18 Li XQ, Bai YL, Zhang DL, Jiao HS, He RX. Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest. Onco Targets Ther 2018;11:4395-405. [PMID: 30100745 DOI: 10.2147/OTT.S166018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, Tomao F, Tomao S, Mancini E, Vincenzoni C, Barba M, Maugeri-Saccà M, Giovinazzo G, Venuti A. Emerging biological treatments for uterine cervical carcinoma. J Cancer 2014;5:86-97. [PMID: 24494026 DOI: 10.7150/jca.7963] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
20 Panahi HA, Bolhassani A, Javadi G, Noormohammadi Z, Agi E. Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses. Immunotherapy 2020;12:459-79. [DOI: 10.2217/imt-2019-0196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 2013;85:303-14. [PMID: 22883215 DOI: 10.1016/j.critrevonc.2012.07.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
22 Lorenz FKM, Ellinger C, Kieback E, Wilde S, Lietz M, Schendel DJ, Uckert W. Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy. Hum Gene Ther 2017;28:1158-68. [PMID: 28950731 DOI: 10.1089/hum.2017.122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
23 Zhao Y, Baldin AV, Isayev O, Werner J, Zamyatnin AA Jr, Bazhin AV. Cancer Vaccines: Antigen Selection Strategy. Vaccines (Basel) 2021;9:85. [PMID: 33503926 DOI: 10.3390/vaccines9020085] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Huang K, Liu R, Peng Q, Li Z, Jiang L, Guo S, Zhou Q, Liu T, Deng C, Yao K, Qin Z, Liu Z, Li Y, Han H, Zhou F. EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis. Urologic Oncology: Seminars and Original Investigations 2019;37:71-7. [DOI: 10.1016/j.urolonc.2018.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Benedetti Panici P, Tomao S. Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther 2014;7:2237-48. [PMID: 25506227 DOI: 10.2147/OTT.S68286] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
26 Son ES, Kim SH, Kim YO, Lee YE, Kyung SY, Jeong SH, Kim YJ, Park JW. Coix lacryma-jobi var. ma-yuen Stapf sprout extract induces cell cycle arrest and apoptosis in human cervical carcinoma cells. BMC Complement Altern Med 2019;19:312. [PMID: 31729992 DOI: 10.1186/s12906-019-2725-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Wang SJ, Zheng CJ, Peng C, Zhang H, Jiang YP, Han T, Qin LP. Plants and cervical cancer: an overview. Expert Opin Investig Drugs 2013;22:1133-56. [PMID: 23789984 DOI: 10.1517/13543784.2013.811486] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
28 Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther 2016;16:83-98. [PMID: 26568261 DOI: 10.1586/14737140.2016.1121108] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 7.7] [Reference Citation Analysis]
29 Hemmat N, Mokhtarzadeh A, Aghazadeh M, Jadidi-Niaragh F, Baradaran B, Bannazadeh Baghi H. Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer. Mol Biol Rep 2020;47:4553-68. [PMID: 32383136 DOI: 10.1007/s11033-020-05494-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kumar A, Yadav IS, Hussain S, Das BC, Bharadwaj M. Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: An in silico approach. Biologicals 2015;43:344-8. [PMID: 26212000 DOI: 10.1016/j.biologicals.2015.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
31 Tummers B, Goedemans R, Pelascini LP, Jordanova ES, van Esch EM, Meyers C, Melief CJ, Boer JM, van der Burg SH. The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. Nat Commun 2015;6:6537. [PMID: 26055519 DOI: 10.1038/ncomms7537] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
32 Qmichou Z, Khyatti M, Berraho M, Ennaji MM, Benbacer L, Nejjari C, Benjaafar N, Benider A, Attaleb M, El Mzibri M. Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women. BMC Infect Dis. 2013;13:378. [PMID: 23953248 DOI: 10.1186/1471-2334-13-378] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
33 Barillari G, Monini P, Sgadari C, Ensoli B. The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. Int J Mol Sci 2018;19:E1418. [PMID: 29747434 DOI: 10.3390/ijms19051418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
34 Parida S, Pal I, Parekh A, Thakur B, Bharti R, Das S, Mandal M. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis 2016;7:e2154. [PMID: 27010855 DOI: 10.1038/cddis.2016.61] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
35 Yoysungnoen B, Bhattarakosol P, Changtam C, Patumraj S. Effects of Tetrahydrocurcumin on Tumor Growth and Cellular Signaling in Cervical Cancer Xenografts in Nude Mice. BioMed Research International 2016;2016:1-11. [DOI: 10.1155/2016/1781208] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
36 Cordeiro MN, Paolini F, Massa S, Curzio G, Illiano E, Duarte Silva AJ, Franconi R, Bissa M, Morghen Cde G, de Freitas AC, Venuti A. Anti-tumor effects of genetic vaccines against HPV major oncogenes. Hum Vaccin Immunother 2015;11:45-52. [PMID: 25483514 DOI: 10.4161/hv.34303] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
37 Wang T, Yan J, Xu W, Ai Q, Mai K. Characterization of Cyclooxygenase-2 and its induction pathways in response to high lipid diet-induced inflammation in Larmichthys crocea. Sci Rep 2016;6:19921. [PMID: 26830811 DOI: 10.1038/srep19921] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]